BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 11372026)

  • 1. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1.
    Kum WW; Chow AW
    J Infect Dis; 2001 Jun; 183(12):1739-48. PubMed ID: 11372026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
    Kum WW; Laupland KB; Chow AW
    Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody.
    Pang LT; Kum WW; Chow AW
    Infect Immun; 2000 Jun; 68(6):3261-8. PubMed ID: 10816471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
    Arad G; Levy R; Hillman D; Kaempfer R
    Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock.
    Arad G; Hillman D; Levy R; Kaempfer R
    J Leukoc Biol; 2001 Jun; 69(6):921-7. PubMed ID: 11404377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.
    LeClaire RD; Bavari S
    Antimicrob Agents Chemother; 2001 Feb; 45(2):460-3. PubMed ID: 11158741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens.
    Bavari S; Ulrich RG; LeClaire RD
    J Infect Dis; 1999 Oct; 180(4):1365-9. PubMed ID: 10479174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1.
    Miethke T; Duschek K; Wahl C; Heeg K; Wagner H
    Eur J Immunol; 1993 Jul; 23(7):1494-500. PubMed ID: 8325325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superantigen and endotoxin synergize in the induction of lethal shock.
    Blank C; Luz A; Bendigs S; Erdmann A; Wagner H; Heeg K
    Eur J Immunol; 1997 Apr; 27(4):825-33. PubMed ID: 9130631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpurulent response to toxic shock syndrome toxin 1-producing Staphylococcus aureus. Relationship to toxin-stimulated production of tumor necrosis factor.
    Fast DJ; Schlievert PM; Nelson RD
    J Immunol; 1988 Feb; 140(3):949-53. PubMed ID: 3339245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defense against biologic warfare with superantigen toxins.
    Kaempfer R; Arad G; Levy R; Hillman D
    Isr Med Assoc J; 2002 Jul; 4(7):520-3. PubMed ID: 12120463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A broad-spectrum inhibitory peptide against staphylococcal enterotoxin superantigen SEA, SEB and SEC.
    Wang S; Li Y; Xiong H; Cao J
    Immunol Lett; 2008 Dec; 121(2):167-72. PubMed ID: 19028523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.
    Cui JC; Hu DL; Lin YC; Qian AD; Nakane A
    FEMS Immunol Med Microbiol; 2005 Jul; 45(1):45-51. PubMed ID: 15985222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staphylococcus aureus isogenic mutant, deficient in toxic shock syndrome toxin-1 but not staphylococcal enterotoxin A production, exhibits attenuated virulence in a tampon-associated vaginal infection model of toxic shock syndrome.
    De Boer ML; Kum WW; Chow AW
    Can J Microbiol; 1999 Mar; 45(3):250-6. PubMed ID: 10408098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind to distinct sites on HLA-DR and HLA-DQ molecules.
    Scholl PR; Diez A; Geha RS
    J Immunol; 1989 Oct; 143(8):2583-8. PubMed ID: 2551962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-production of staphylococcal enterotoxin A with toxic shock syndrome toxin-1 (TSST-1) enhances TSST-1 mediated mortality in a D-galactosamine sensitized mouse model of lethal shock.
    De Boer ML; Kum WW; Pang LT; Chow AW
    Microb Pathog; 1999 Aug; 27(2):61-70. PubMed ID: 10458917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist properties of a microbial superantigen peptide.
    Pontzer CH; Griggs ND; Johnson HM
    Biochem Biophys Res Commun; 1993 Jun; 193(3):1191-7. PubMed ID: 8323541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of function between the domains of toxic shock syndrome toxin-1.
    Wahlsten JL; Ramakrishnan S
    J Immunol; 1998 Jan; 160(2):854-9. PubMed ID: 9551921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-linking staphylococcal enterotoxin A bound to major histocompatibility complex class I is required for TNF-alpha secretion.
    Wright AD; Chapes SK
    Cell Immunol; 1999 Nov; 197(2):129-35. PubMed ID: 10607430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection.
    Hu DL; Omoe K; Sasaki S; Sashinami H; Sakuraba H; Yokomizo Y; Shinagawa K; Nakane A
    J Infect Dis; 2003 Sep; 188(5):743-52. PubMed ID: 12934191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.